Impact of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis in Hospitalized Infants: A Real-World Study
Éric Jeziorski, Antoine Ouziel, Marie Cotillon, Constance Bridonneau, Etienne Bizot, Clément Basse, Aurélie Portefaix, François Dubos, Stéphane Béchet, L. Domitien, Carine Jaillet, Sorin Abrudan, Rolf Kramer, Vincent Gajdos, É. Launay, Romain Basmaci, Yves Gillet, Robert Cohen, Corinne Levy
Abstract
Regarding nirsevimab immunization status, among 1085 infants hospitalized for bronchiolitis, the odds of hospitalization for respiratory syncytial virus bronchiolitis were 4.7 times higher for nonimmunized children. Immunized infants were less likely to require oxygen supplementation (20.2% vs. 30.6%, P = 0.02) and had a 1-day shorter hospital stay. Respiratory syncytial virus bronchiolitis was less frequent and less severe in infants immunized with nirsevimab.